Adagene's CTLA-4 Masking Antibody Data to be Presented at AACR
Event summary
- Adagene (ADAG) will present data on its lead clinical program, muzastotug (ADG126), at the 2026 AACR Annual Meeting in San Diego, CA, April 17-22.
- Two poster presentations will focus on Phase 1b and Phase 1b/2 trials: one in combination with pembrolizumab and fruquintinib for colorectal cancer, and another in combination for hepatocellular carcinoma (HCC).
- Muzastotug is a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation, targeting Tregs in the tumor microenvironment.
- The presentations will occur on April 20, 2026, between 9:00 AM and 12:00 PM Pacific Time.
The big picture
Adagene's approach to masking CTLA-4 to reduce toxicity represents a significant effort to improve immunotherapy outcomes, particularly in patient populations like MSS colorectal cancer that have historically been resistant to checkpoint inhibitors. The company's SAFEbody platform aims to address a key limitation of current antibody therapies, potentially broadening the applicability of immunotherapy and creating a competitive advantage. The AACR presentations will provide early insights into whether this strategy is translating into clinical benefit.
What we're watching
- Clinical Efficacy
- The data presented at AACR will be critical in assessing the early clinical efficacy of muzastotug in combination therapies, particularly given the focus on microsatellite stable colorectal cancer where existing treatments have limited effectiveness.
- SAFEbody Adoption
- The success of muzastotug will influence the broader adoption of Adagene’s SAFEbody platform across other antibody-based therapies, potentially impacting the company’s licensing and partnership opportunities.
- Regulatory Pathway
- The FDA Fast Track designation suggests an accelerated regulatory pathway, but the data presented at AACR will be closely scrutinized to determine if this timeline remains feasible.
Related topics